GlassScriptPhysician profile
Cornelius J Mance
NPI 1861586331
$17,341.50
in general payments reported to CMS, 2019-2025
64 companies · $2,427 in 2025
The $2,427 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,040 · 2020: $2,064 · 2021: $2,681 · 2022: $2,241 · 2023: $2,378 · 2024: $2,509 · 2025: $2,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,314.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,259.59 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $1,180.27 | 2019-2025 | Uplizna, Aimovig |
| Neurocrine Biosciences, INC. | $1,133.99 | 2019-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $1,103.71 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Abbvie INC. | $894.31 | 2021-2025 | |
| Ucb, INC. | $834.34 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Acadia Pharmaceuticals INC | $766.43 | 2019-2025 | Nuplazid |
| Lilly USA, LLC | $730.70 | 2019-2025 | Kisunla, Amyvid, Reyvow |
| Eisai INC. | $561.57 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $548.71 | 2019-2025 | |
| Celgene Corporation | $525.01 | 2021-2024 | Zeposia |
| Avanir Pharmaceuticals, INC. | $497.12 | 2019-2022 | |
| Neurelis, INC. | $470.77 | 2020-2025 | Valtoco |
| Lundbeck LLC | $460.05 | 2020-2025 | Vyepti, Rexulti |
| Genzyme Corporation | $456.79 | 2019-2023 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cornelius Mance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.